BioTissue Holdings Inc. With a strong commitment to improving patient outcomes, BioTissue offers a range of products and services tailored to the needs of both ocular and surgical patients. For ocular patients, BioTissue provides cutting-edge solutions such as Prokera, AmnioGraft, and AmnioGuard, which harness the power of regenerative medicine to promote healing in a natural and effective manner.

Surgical patients can benefit from products like Neox 100, Neox 1K, Neox RT, Clarix 100, and Clarix 1K, which are backed by the company's proprietary cryopreservation technology called CryoTek®. BioTissue's extensively researched and clinically tested allografts have been proven to retain the structure and biology of natural tissue, facilitating regenerative healing. With over 38 years of research and development, 800,000+ human clinical applications, and 390+ peer-reviewed publications, BioTissue is at the forefront of the regenerative medicine field.

Driven by a commitment to ethical conduct and regulatory compliance, BioTissue is shaping the future of regenerative medicine. By partnering with physicians, healthcare professionals, and patients, BioTissue is revolutionizing wound healing and changing lives for the better